| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Biology, Pathobiology and Genetics |
Departments of 1 Epidemiology, 2 Veterinary Medicine and Surgery, 3 Molecular Genetics, and 4 Pathology, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas
Requests for reprints: Marsha L. Frazier, Department of Epidemiology, The University of Texas, M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: 713-792-3393; Fax: 713-563-0999; E-mail: mlfrazier{at}mail.mdanderson.org.
| Abstract |
|---|
|
|
|---|
2 months earlier than Lkb1+//p53+/ and Lkb1+/ mice, whereas the latter two show a similar time to onset which is at
6 months of age. These results strongly suggested that mutations of p53 and Lkb1 gene cooperate in the acceleration of tumorigenesis. (Cancer Res 2005; 65(24): 11297-303) | Introduction |
|---|
|
|
|---|
Numerous studies have indicated a tumor-suppressive function for LKB1. This gene has been implicated in the regulation of multiple biological processes and signaling pathways. Restoring LKB1 activity into cancer cell lines defective for its expression results in a G1 cell cycle arrest (13) by inducing the expression of p21WAF1/CIP1 through a p53-dependent mechanism (14). The involvement of LKB1 in upstream signaling to AKT and the PI3 kinase pathway (15) indicates the importance of this gene as a regulator of cell growth. It has also been reported that LKB1 (XEEK1) regulates Wnt signaling in vertebrate development (16). Shaw et al. (17) showed that LKB1 directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Another study (18) shows that LKB1 regulates 13 kinases of the AMPK subfamily. Taken together, these data suggest that LKB1 plays an important role in tumorigenesis.
The p53 gene is the most intensively studied tumor suppressor gene, which produces a protein product that functions as a transcription factor. Close to half of all human cancers have p53 gene mutations, indicating that loss of its function is a critical event in tumor progression (19). Studies of p53 mouse models have revealed a key function of p53 in inhibition of cell proliferation and induction of cell apoptosis. A p53 null allele has been generated in mice by several groups and the conclusions are similar (2023). Jacks and colleagues (20) constructed a mouse strain on a C57BL/6J background carrying a p53 mutant allele, which deleted
40% of the p53 coding region and completely eliminated synthesis of the p53 protein. Mice homozygous for this mutant allele are viable but highly predisposed to malignancy and most of them die by 6 months of age. Mice heterozygous for this mutant allele are also susceptible to tumors, predominantly sarcoma, osteosarcoma, and lymphomas;
50% of these mice die by 18 months of age. Studies on these mice lacking one or two copies of the p53 gene have provided invaluable insight into the process of tumorigenesis.
There is evidence to suggest that LKB1 plays a key role in p53-mediated apoptosis (24). Loss of heterozygosity (LOH) at 17p as well as overexpression of p53, indicative of p53 gene mutation, was seen in adenocarcinomas associated with PJS (25). In order to study the interaction between LKB1 and p53, we generated heterozygous mice with a targeted inactivating mutation of Lkb1, and then crossed this line with the p53 null mice mentioned above (20) to obtain double knockout mice for Lkb1 and p53 genes. As our data show, gastrointestinal hamartomatous polyps occur with similar frequency and the onset of polyposis occurs at roughly the same age in both Lkb1+/ and Lkb1+//p53+/ mice. In contrast, the doubly heterozygous mice have a dramatically increased incidence of tumors characteristic of p53 knockout mice. Furthermore, the time to onset of polyposis in Lkb1+//p53/ is
2 months earlier than Lkb1+//p53+/ and Lkb1+/ mice. All these results suggest that Lkb1 and p53 cooperate synergistically in tumorigenesis. Thus, our mouse models of human PJS should be useful in future studies aimed at revealing the mechanisms of action of LKB1, as well as developing novel preventive and therapeutic strategies.
| Materials and Methods |
|---|
|
|
|---|
Cloning of mouse Lkb1 gene fragments by PCR. A clone (clone 82) was obtained after screening the mouse library
DASH-2 by hybridization with mouse Lkb1 exon 1 PCR product. Sequencing showed that clone 82 contains exon 1 and part of intron 1 of the mouse Lkb1 gene. Sequencing also allowed us to identify a forward primer (CJ1, 5'-TTGGTCTGGGCAAGTAGACACA-3'), which was used along with a reverse primer (exon 2R, 5'-CTGCTTCTCCTCATTGTACAGC-3') to amplify the intron 1 fragments. Also, the regions of exons 2 to 8 (2-8F, 5'-GGCAGGGTCAGCTAAGCAATGT-3'; 2-8R, GGAGACACAGTAGCCCAAGGTC-3') and intron 8 (3 arm F1, 5'-GAGGAGGAGGA GGAGGAAGACT-3'; 3 arm R, 5'-TCCATTCTGACCCACTTCCTCT-3') were amplified separately by using the normal mouse genomic DNA as template. A TOPO XL PCR Cloning Kit (Invitrogen Corporation, San Diego, CA) was used to obtain a clone (clone 1) for the intron 1 fragment, a clone (clone B38) for the exon 2 to 8 fragment, and a clone (clone 13) for the intron 8 fragment, respectively. After sequencing, intron 1 was found to be 7894 bp in length (data not shown).
Generation of Lkb1 knockout mice. The 5' homologous arm was cloned into the pBluescript II SK plasmid vector by ligating together the following three fragments one by one: a loxP sequence (5'-ATAACTTCGTATAGCATACATTATACGAAGTTAT-3') attached with ClaI site, the PCR product of the primer pair of 5 arm 3' F and 5 arm 3' R (5 arm 3' F, 5'-CGGAATTCGGCCATTGCCTGGGTATC-3'; 5 arm 3' R, 5'-CCATCGATGCCTGCTGTGAGAAGCCTACAT-3') digested with HindIII and ClaI, and the fragment resulting from clone 1 digested with KpnI and HindIII. Then the following fragments were inserted one by one into the resulting clone: a fragment of phosphoglycerate kinase-neo (neomycin resistance) gene cassette flanked by two loxP sites, a fragment of the thymidine kinase gene cassette as a negative selection marker, a fragment containing exons 2 to 8 resulting from digestion of clone B38 with EcoRI (originating from the polylinker) and AvaI, and a 3' homologous arm fragment resulting from the digestion of clone 13 with AvaI and ApaI (Fig. 1A). The targeting vector was sequenced to verify that no errors had been produced in the process of cloning. AB-1 embryonic stem cells were transfected with the linearized targeting vector by electroporation. Cells were selected for resistance to G418 and 1-(2-deoxy-2-fluoro-D-arabinofuranosyl)-5-iodouracil. Southern blot analysis was done to identify clones in which the expected homologous recombination event had occurred at both 5' and 3' ends (Fig. 1C). These clones were then injected into C57BL/6J blastocysts. To obtain Lkb13loxP heterozygous mutants, male chimeras were mated with C57BL/6J females purchased from The Jackson Laboratory (Bar Harbor, ME). To produce null mutant mice in which the region containing exons 2 to 8 had been deleted, Lkb13loxP/+ mice were mated with CMV-Cre transgenic mice (26). The first generation resulting from this mating was mosaic, and the genotype was screened by PCR (data not shown). Then the mosaic mice were mated with C57BL/6J mice to separate the three different genotypes resulting from Cre-mediated recombination (Fig. 1B). Southern blot analysis and PCR were done on the DNA extracted from the tip of mice tails to screen the genotype.
|
Kaplan-Meier survival analysis. STATA software (StataCorp, College Station, TX) was used for survival curve analysis and tumor-free survival analysis. Statistical significance between genotypes was determined using built-in analysis for survival curves consisting of a log rank test yielding a P value.
Loss of heterozygosity analysis. Genomic DNA from paraffin embedded tissue was extracted using QIAamp DNA mini Kit (Qiagen Inc., Valencia, CA). Two sets of primers were used to detect the targeted Lkb1 allele (primer a, 5'-TGTCCTGGTGGTCCTTCTC-3'; and primer e, 5'-ACAGGGAGCTACACTAAAG-3') and the wild-type Lkb1 allele (primer 3 arm F, 5'-GAGGAGGAGGAGGAGGAAGAC-3' and primer e), respectively. The multiplex PCR was done for 10 minutes at 94°C followed by 30 cycles at 94°C for 30 seconds, 58°C for 45 seconds, and 72°C for 1 minute, and a final extension step at 72°C for 10 minutes.
| Results |
|---|
|
|
|---|
Survival and polyposis in Lkb1+/ mice. Lkb1+/ mice were found to have reduced life spans with
50% dying by 14 months compared with their wild-type littermates (Fig. 2A). Their abdomens became increasingly distended as they aged. Complete necropsies were done on 46 Lkb1+/ mice that became moribund and were sacrificed at ages ranging from 6 to 18 months. At necropsy, gastrointestinal polyps were identified in Lkb1+/ mice as early as 6 months of age and in
75% of mice at age of 6.5 months. Most polyps were located at the junction of the pylorus and duodenum, and a small number of polyps were found in the antrum or fundus of the stomach. No polyps were found in other parts of the gastrointestinal tract including the large intestine (Table 1). In the majority of animals that we examined, polyps originating from the pylorus were large, whereas polyps located in the fundus and antrum were smaller. The large polyps in the pylorus protruded into the duodenum, resulting in gross distension and obstruction of the duodenum (Fig. 3A and B). These obstructions, which mimic the clinically acute obstruction seen in many cases of human PJS, seem to explain the high mortality of the Lkb1+/ mice.
|
|
|
Out of 13 Lkb1+/ mice with complete histologic assessment of all of the organs, 9 (69%) exhibited organomegaly of spleen, lung, liver, stomach, and intestine. No other neoplasms or tumors were observed.
Survival and polyposis in Lkb1+//p53+/ and Lkb1+//p53/ mice. As mentioned above, current evidence suggests that Lkb1 regulates p53-dependent apoptosis, and loss of p53 is an important factor in tumor development. To determine whether Lkb1 and p53 mutations act synergistically in tumorigenesis, we mated Lkb1 heterozygous knockout mice with p53 homozygous knockout mice (20) to generate a series of mice heterozygous for both mutations (Lkb1+//p53+/). A population of 129 mice carrying a mutant allele of both Lkb1 and p53 were generated and monitored. Lkb1+//p53+/ mice were found to have reduced life spans with
50% dying by 10 months (Fig. 2B). The median age of survival of Lkb1+//p53+/ mice (10 months) was dramatically lower than that of mice heterozygous for the Lkb1 or p53 mutation alone (14 and 18 months, respectively).
Similar to Lkb1+/ mice, Lkb1+//p53+/ mice had enlarged abdomens due to hamartomatous polyps in the pylorus and duodenum (Fig. 3C). Mice that became moribund were euthanized and subjected to a complete necropsy. Ninety-two percent (35 out of 38) of the moribund Lkb1+//p53+/ mice ranging in age from 7 to 14 months showed polyps in their gastrointestinal tract. The majority of these mice had polyps in the stomach and/or duodenum (Table 1). One mouse also displayed colonic polyps. We compared the time to onset of polyposis observed in Lkb1+/ to that seen in Lkb1+//p53+/ mice. Necropsy was done on the randomly selected Lkb1+//p53+/ mice at different time points. Polyps could not be detected in the mice younger than 5.5 months (four out of four), but were detected in 60% of mice (three out of five) at 6.5 months. This result is similar to the time to onset of polyposis observed in Lkb1+/ mice. In addition, both intensity (data not shown) and the histologic appearance (Fig. 3G) of the polyps in Lkb1+//p53+/ mice were very similar to those in Lkb1+/ mice. Thus, it is very possible that loss of one allele of p53 is not enough to accelerate the polyposis. To further evaluate whether p53 plays a role in polyposis, a cohort of 20 mice nullizygous for p53 and containing one mutant Lkb1 allele (Lkb1+//p53/) mice were generated and monitored. The median age of survival of Lkb1+//p53/ mice was
4.5 months which is very similar to their littermate p53/ mice (Fig. 2C). Necropsy studies revealed that gastrointestinal hamartomatous polyps (Fig. 3D) in Lkb1+//p53/ mice were identified as early as 4.3 months. This is
2 months earlier than those for Lkb1+//p53+/ mice, no time difference was observed between the Lkb1+/ and Lkb1+//p53+/ mice. Although the histologic appearance of these polyps from Lkb1+//p53/ mice (Fig. 3H) are very similar to the polyps identified in the Lkb1+/ and Lkb1+//p53+/ mice, the difference in the polyps locations were observed as two out of seven mice also had polyps in their large intestines. These findings suggested that the knockout p53 gene in the Lkb1+/ mice increases the time to onset of polyposis and influence the distribution of polyps.
Tumorigenesis in Lkb1+//p53+/ and Lkb1+//p53/ mice. In addition to the gastrointestinal polyps, a variety of tumors were also found in the Lkb1+//p53+/ and Lkb1+//p53/ mice (Table 2; Fig. 4). Twenty-three (61%) of 38 Lkb1+//p53+/ mice developed a total of 30 tumors. Among them, 13 (43%) of these tumors were osteosarcomas, 3 (10%) were sarcomas, and 6 (20%) were lymphomas. These tumor types are the characteristic tumor types detected in the mice heterozygous for p53. In Lkb1+//p53+/ mice, osteosarcoma is the predominant one, which is very similar to the dominant tumor type reported previously (2023) as well as in their p53+/ littermate presented here. Also, we did a tumor-free survival analysis on the Lkb1+//p53+/ and p53+/ mice that underwent necropsy. The median age of tumor-free survival for Lkb1+//p53+/ mice was 11 months, whereas for p53+/ mice, it was
17 months (Fig. 5A), this difference was statistically significant (P < 0.01) suggesting that Lkb1+//p53+/ mice had a significant increase in tumor incidence compared with the p53+/ mice.
|
|
|
The Lkb1+//p53/ mice were highly susceptible to tumors at an early age, particularly malignant lymphoma (Table 2). Carcinoma of the pancreas, mammary gland, and small intestines, observed in Lkb1+//p53+/ mice at >10 months of age, were not observed in the Lkb1+//p53/ mice, probably due to the severely compromised life span.
Together, these findings showed that the loss of the p53 gene accelerates the time to onset of polyposis in Lkb1+/ mice and the added deletion of the Lkb1 gene dramatically increased tumor incidence in p53+/ mice and strongly suggests that mutation of both Lkb1 and p53 genes did have a cooperative effect on tumorigenesis.
| Discussion |
|---|
|
|
|---|
2 months, although the time to onset of polyposis (
6 months) in Lkb1+//p53+/ mice was not very different from that in Lkb1+/ mice. Taken together, these findings suggest that the interaction between these two tumor suppressor genes in the gastrointestinal tract had a cooperative effect on polyposis. LKB1 has been reported as a mediator of p53-dependent apoptosis and a player in cell cycle arrest. Therefore, to evaluate the joint effects of the Lkb1 and p53 genes on tumorigenesis, Lkb1+//p53+/ and Lkb1+//p53/ mice were generated. Hamartomatous polyps in the gastrointestinal tracts as well as various other types of tumors have been detected in mice with these two genotypes. Compared with the Lkb1+/ mice present here as well as the Lkb1+/ mice reported by other groups (28, 29, 33), Lkb1+//p53+/ mice showed a dramatically increased incidence of various types of tumors including malignant cancers of the pancreas, mammary gland, and intestinal organs, which are the most common tumor types seen in PJS. Thus, the Lkb1+//p53+/ mouse line provide a model for tumor formation for PJS. Although the tumor spectrum in Lkb1+//p53+/ mice is not identical to that observed in human patients with PJS, this is the first mouse model of PJS in which a significant incidence of various types of tumors was observed.
The Lkb1+//p53/ mice presented here also showed various types of tumors which are characteristic tumor types detected in p53-deficient mice. However, no PJS-predisposed cancer type was observed, which was most likely due to the severely compromised longevity. Meanwhile, the survival curve of the Lkb1+//p53/ and p53/ are very similar to each other, suggesting that LKB1 and p53 may function in the same apoptotic pathway. Recently, Jones et al. (34) reported that AMPK activation induces phosphorylation of p53 on serine 15 and this phosphorylation is required to initiate AMPK-dependent cell cycle arrest in response to the glucose deprivation. Meanwhile, Shaw et al. (17) showed that LKB1 directly activates AMPK and regulates apoptosis in response to energy stress. These findings suggest that regulation of p53-dependent apoptosis by LKB1 is likely to occur through the activation of AMPK. Further studies need to be done to elucidate the possible linkage between the Lkb1, AMPK, and p53. Several mouse cross-breeding studies have shown cooperation between p53 and other tumor suppressor genes or oncogenes (35, 36). For example, mutation of both Rb and p53 (Rb+//p53+/) produces mice that have shorter life spans and develop a variety of tumors not found in mice with single gene mutations. This also happened in Lkb1+//p53+/ mice. Furthermore, it is very possible that LKB1 is in the p53-dependent pathway, loss of one wild-type allele of Lkb1 and p53 both contribute to the tumorigenesis because the p53-dependent pathway is not entirely inactive and the efficiency of the pathway could be decreased through partial loss of LKB1. Together, our data suggests that Lkb1 and p53 cooperate in the acceleration of tumorigenesis.
LOH contributes to tumor formation when cells are heterozygous for a mutant allele of a tumor suppressor gene. To further understand how LKB1 is involved in tumor formation, LOH analysis was done on the genomic DNA extracted from tumors observed in Lkb1+//p53+/ mice as well as in mouse tail tissue. In one adenocarcinoma of the small intestine and one lymphoma, the PCR product of wild-type alleles displayed a decrease in intensity compared with the knockout alleles, suggesting that LOH had occurred for Lkb1. Although in the rest of the samples, both wild-type and knockout alleles are comparably amplified, suggesting that the wild-type allele was retained. For the samples where LOH was not observed, we cannot rule out the possibility that the Lkb1 wild-type allele was inactivated by a localized mutation (i.e., small insertion/deletion or point mutations) because we did not sequence the wild-type gene.
In conclusion, we have described different Lkb1+/ mouse lines with or without p53 mutation for human PJS and have shown that the Lkb1 and p53 genes cooperate in tumorigenesis. Our findings also suggest that our Lkb1+/ and Lkb1+//p53+/ mice will be an important and useful model in which to elucidate the molecular mechanisms underlying PJS polyposis and tumorigenesis. Crossing the Lkb1 knockout mouse with other cancer-prone mouse strains will also help to establish the mechanism of action of Lkb1 by revealing genetic interactions between Lkb1 and other genes important in tumor development.
| Acknowledgments |
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
We thank Haidee Chancoco for DNA extraction and PCR analysis, and Jingyun Chen for mice maintenance assistance.
Received 3/ 2/05. Revised 9/ 6/05. Accepted 9/30/05.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
M. Jansen, J. P. ten Klooster, G. J. Offerhaus, and H. Clevers LKB1 and AMPK Family Signaling: The Intimate Link Between Cell Polarity and Energy Metabolism Physiol Rev, July 1, 2009; 89(3): 777 - 798. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Dorfman and I. G. Macara STRAD{alpha} Regulates LKB1 Localization by Blocking Access to Importin-{alpha}, and by Association with Crm1 and Exportin-7 Mol. Biol. Cell, April 1, 2008; 19(4): 1614 - 1626. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Wei, C. I. Amos, N. Zhang, X. Wang, A. Rashid, C. L. Walker, R. R. Behringer, and M. L. Frazier Suppression of Peutz-Jeghers Polyposis by Targeting Mammalian Target of Rapamycin Signaling Clin. Cancer Res., February 15, 2008; 14(4): 1167 - 1171. [Abstract] [Full Text] [PDF] |
||||
![]() |
P.-Y. Zeng and S. L. Berger LKB1 Is Recruited to the p21/WAF1 Promoter by p53 to Mediate Transcriptional Activation. Cancer Res., November 15, 2006; 66(22): 10701 - 10708. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Marshall Role of Insulin, Adipocyte Hormones, and Nutrient-Sensing Pathways in Regulating Fuel Metabolism and Energy Homeostasis: A Nutritional Perspective of Diabetes, Obesity, and Cancer Sci. Signal., August 1, 2006; 2006(346): re7 - re7. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |